問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Taichung Veterans General Hospital

Link to Hospital

  • 1,624

    Total Beds

  • 934

    Total Doctors

  • tcvghcrc@vghtc.gov.tw
  • Clinical Research Center
  • 04-23592525#4780
  • 407Taichung CityTaichung Xitun1650 Taiwan Boulevard Sect. 4, Taichung, Taiwan 407219, ROC

Recruiting Trial

585Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1360Cases

2021-05-01 - 2025-12-31

Phase II/III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
14Sites

Recruiting12Sites

2021-05-18 - 2023-12-31

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting5Sites

Terminated5Sites

2021-05-31 - 2026-09-30

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2021-08-01 - 2021-09-27

Phase I/II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Terminated2Sites

2025-06-16 - 2029-09-30

Active
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY® Study)

  • Condition/Disease

    Bronchiectasis

  • Test Drug

    BI 1291583 or matching placebo

Participate Sites
6Sites

Recruiting6Sites

2018-09-26 - 2022-05-18

Phase III

Active
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

  • Condition/Disease

    Unresectable Locally Advanced Urothelial Cancer Metastatic Urothelial Cancer

  • Test Drug

    Durvalumab (MEDI4736)/TREMELIMUMAB

Participate Sites
7Sites

Recruiting6Sites

蘇柏榮
Linkou Chang Gung Medical Foundation

2026-06-01 - 2028-12-31

Phase II

Not yet recruiting
A phase IIb trial (ARGiNAUT) evaluating the efficacy, safety, and tolerability of AZD8965 in patients with idiopathic pulmonary fibrosis (IPF).

  • Condition/Disease

    Idiopathic pulmonary fibrosis

  • Test Drug

    AZD8965 Film-Coated Tablet

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting1Sites

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
A randomized, double-blind, parallel-group, phase 3 trial was conducted to evaluate the efficacy, safety, and tolerability of elecoglipron compared to placebo in adult patients with type 2 diabetes, impaired renal function, and receiving background treatment with dapagliflozin (Eluminate-4).

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    Dapagliflozin Elecoglipron

Participate Sites
12Sites

Not yet recruiting1Sites

2018-12-06 - 2026-03-31

Phase II

Active
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients with Advanced Neuroendocrine Tumors

  • Condition/Disease

    Neuroendocrine Tumors Pancreatic Neuroendocrine Tumor Gastro-enteropancreatic Neuroendocrine Tumor Lung Neuroendocrine Neoplasm Neuroendocrine Carcinoma

  • Test Drug

    CVM-1118 Capsules

Participate Sites
8Sites

Recruiting3Sites

Terminated4Sites

陳明晃
Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2018-12-01 - 2019-11-07

Phase I

Active
A Phase I Multicenter Study of Immunotherapy in Combination with Chemoradiation in Patients with Advanced Solid Tumors (CLOVER)

  • Condition/Disease

    Carcinoma, Squamous Cell of Head and Neck Carcinoma, Non-Small-Cell Lung Small Cell Lung Carcinoma

  • Test Drug

    Durvalumab (MEDI4736) Tremelimumab

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting3Sites

1 3 4 5 6 7 136
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB